Roflumilast Boosts Semaglutide's cAMP Signal, Extending Weight-Loss Effect

In mice, blocking the cAMP‑degrading enzyme PDE4 with roflumilast keeps semaglutide’s signal alive in the brain’s appetite hub.

Inside the Area Postrema

The area postrema, a small hindbrain region that monitors blood chemistry and drives satiety, houses GLP‑1 receptors. Using two‑photon fluorescence imaging in living mouse tissue, Claire Gao and colleagues mapped how semaglutide, a GLP‑1 receptor agonist, elevates intracellular cAMP. They found that cAMP rises vary dramatically from neuron to neuron—some cells maintain high levels for hours, while others spike briefly before the signal fades.

PDE4 Inhibition Turns Transient into Sustained

Michael Krashes explained that the transient responses likely stem from receptor internalization or degradation. By administering roflumilast, a PDE4 inhibitor, the team prevented cAMP breakdown. The result? A shift toward sustained cAMP elevations across a larger fraction of neurons. This sustained signaling could translate into a longer appetite‑suppressing effect, potentially allowing lower or less frequent dosing of semaglutide.

Implications for GLP‑1 Therapy

Andrew Lutas noted that the weight‑loss benefits of GLP‑1 drugs plateau in many patients. Extending the intracellular signal offers a plausible strategy to break that plateau. While the current experiments span only a few hours, the authors plan to adapt newer imaging techniques to monitor cAMP dynamics over days and weeks.

The study, published in Nature Metabolism (2026), underscores that intracellular signaling nuances matter as much as receptor binding. If PDE4 inhibition can reliably prolong GLP‑1 action in humans, it could reshape obesity treatment by reducing injection burden and improving adherence.

Source: NIH researchers identify avenue for enhanced GLP-1-induced weight loss
Domain: nih.gov